Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Health promotion and disease prevention

Vol. 27 No. 3 (2025)

Prevalence, time of onset and duration of adverse effects of etonogestrel subdermal implant

DOI
https://doi.org/10.22267/rus.252703.350
Submitted
December 9, 2024
Published
2025-09-01

Abstract

Introduction: The subdermal implant is a highly effective family planning option. Identifying adverse effects allows us to understand the epidemiological behavior of this method. Objective: To determine the prevalence, time of onset, and duration of adverse effects of the etonogestrel subdermal implant. Materials and methods: A descriptive cross-sectional design was performed in 50 women who were users of etonogestrel subdermal implants. The types of adverse effects, their number, prevalence, time from onset to application, and duration of the effect from the time of implant application were identified. Results: The average age was 28.84 years (95% CI; 26.98–30.70). The most frequently occurring adverse effect was menstrual irregularities in 98.0% (95% CI: 93.9–100.0); the onset time was 3.31 months (95% CI' 1.40–5.21) after implant application, and the average duration was 35.76 months (95% CI; 26.97–44.54). In women with etonogestrel subdermal implants, 100% experienced one or more adverse effects. Conclusion: The prevalence of adverse effects from the use of etonogestrel subdermal implant is high, and several adverse effects occur at different times and durations.

References

  1. Lopes da Silva Filho A, Luis Pereira Bueno R, Ramires Y, Cruz Lino LM. Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system. PLoS One [Internet]. 2024; 19(3):e0301207. DOI: 10.1371/journal.pone.0301207
  2. Moeti DMP, Govender I, Bongongo T. Early removal of etonogestrel subcutaneous contraceptive implant at a community health centre in Pretoria. S Afr Fam Pract [Internet]. 2022; 64(1):e1–e6. DOI: 10.4102/safp.v64i1.5407
  3. Darney BG, Fuentes-Rivera E, Corbin A, Saavedra-Avendano B, Schiavon R. Trends in subdermal contraceptive implant use in Mexico 2009-2018: A population-based study. Int J Gynaecol Obstet [Internet]. 2022; 156(2):284–291. DOI: 10.1002/ijgo.13744
  4. Saurabh S. Implanon: subdermal single rod contraceptive implant. Int J Reprod Contracept Obstet Gynecol [Internet]. 2024; 13(3):711–714. DOI: 10.18203/2320-1770.ijrcog20240482
  5. Bardin CW. Implantable contraception. Curr Ther Endocrinol Metab [Internet]. 1994; 6:263–270. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9174757
  6. Al Jeborry MM, Al Kadhim HKH, Witwit SJ. Assessmen to effectiveness and side effects of subdermal implant among user women. Med J Babylon [Internet]. 2024; 21(2):272–275. DOI: 10.4103/mjbl.mjbl_302_23
  7. Calixto Morales DP, Ospina Díaz JM, Manrique Abril FG. Retiro temprano del implante subdérmico con etonogestrel en usuarias de un programa de anticoncepción de Tunja - Boyacá, Colombia. Univ Salud [Internet]. 2015; 17(2):224–232. DOI: 10.22267/rus.151702.7
  8. Moray KV, Chaurasia H, Sachin O, Joshi B. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reprod Health [Internet]. 2021; 18(1):4. DOI: 10.1186/s12978-020-01054-y
  9. Rocca ML, Palumbo AR, Visconti F, Di Carlo C. Safety and benefits of contraceptives implants: A systematic review. Pharmaceuticals (Basel) [Internet]. 2021; 14(6):548. DOI: 10.3390/ph14060548
  10. Organización Mundial de la Salud. Family planning: a global handbook for providers, 4th ed [Internet]. OMS; 2022 [citado 2025 Jul 15]. Disponible en: https://www.who.int/publications/m/item/family-planning--a-global-handbook-for-providers--4th-ed
  11. Niu X, Luo Q, Wang C, Zhu L, Huang L. Effects of Etonogestrel implants on pelvic pain and menstrual flow in women suffering from adenomyosis or endometriosis: Results from a prospective, observational study. Medicine (Baltimore) [Internet]. 2021; 100(6):e24597. DOI: 10.1097/MD.0000000000024597
  12. Vargas-Arellano A, Barrios-Yáñez F, Pérez-Flores LM, Díaz-Herrera GA. Reasons for early with drawal of etonogestrel subdermal implant. Atención Familiar [Internet]. 2024; 31(4):227–232. DOI: 10.22201/fm.14058871p.2024.489468
  13. García-León FE, López-Benítez SV, Pablos-Vega G, Medina-Ramos G, Ramírez-Diarte EA, Uriarte-Ontiveros S. Frecuencia de efectos adversos en usuarias de implante subdérmico. Rev Enferm Inst Mex Seguro Soc [Internet]. 2011 [citado 2024 Nov 20]; 19(1):21–24. Disponible en: https://www.medigraphic.com/pdfs/enfermeriaimss/eim-2011/eim111e.pdf
  14. Wali R, Alghamdi MA, Ahmed ST, Gammash AM, Bukhari MM, Alkhozam KF, et al. Satisfaction with the use of subdermal contraceptive implant in women attending the Specialized Polyclinic Primary Health Care Center in Jeddah city: A cross-sectional study. Cureus [Internet]. 2023; 15(3):e35902. DOI: 10.7759/cureus.35902
  15. Cuéntame de México. Escolaridad [Internet]. cuentame.inegi.org.mx. [citado 2024 Nov 20]. Disponible en: https://www.cuentame.inegi.org.mx/poblacion/escolaridad.aspx
  16. Martínez-Hernández YI, Villarreal-Ríos E, Galicia-Rodríguez L, Cu-Flores LA. Costo del retiro anticipado de métodos de planificación familiar. Ginecol Obstet Méx [Internet]. 2023 [citado 2024 Nov 20]; 91(2):92-99. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0300-90412023000200092&lng=es
  17. Lasa IL. Eficacia, seguridad y tolerabilidad del implante anticonceptivo de varilla única con etonogestrel. Progr Obstet Ginecol [Internet]. 2020; 63(2):81-93. Disponible en: https://sego.es/documentos/progresos/v63-2020/n2/RC-eficacia-implante-anticonceptivo.pdf
  18. Montenegro-Pereira E, Lara-Ricalde R, Velásquez-Ramírez N. Implantes anticonceptivos. Perinatol Reprod Hum [Internet]. 2005 [citado 2024 Nov 23]; 19(1):31-43. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0187-53372005000100005&lng=es
  19. González-Fernández C, Fernández-Revilla JM. Manejo de los Implantes Subdérmicos de Etonogestrel en Atención Primaria. Rev Clin Med Fam [Internet]. 2011 Jun [citado 2024 Nov 23]; 4(2):146-149. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-695X2011000200010&lng=es
  20. Acosta-León O, Cruz-López K, Rodríguez-Columbié C. Efectos adversos del implante anticonceptivo subdérmico en adolescentes. Rev Cub Med Mil [Internet]. 2019 Sep [citado 2024 Nov 23]; 48(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572019000300006&lng=es
  21. Obsu M, Hundessa B, Garoma S, Aman H, Merga H. Magnitud y factores asociados a la discontinuación temprana de Implanon entre mujeres rurales en instalaciones de salud pública del centro de Etiopía: un estudio comunitario transversal. BMC Womens Health [Internet]. 2022; 22(1):72. DOI: 10.1186/s12905-022-01651-y
  22. Orozco-Galván AI. Anticoncepción forzada en mujeres mexicanas realizadas en instituciones públicas de salud: una aproximación etnográfica. Enferm Univ [Internet]. 2021; 18(4). DOI: 10.22201/eneo.23958421e.2021.4.1238
  23. Quintero-Veloz X, Vallin J, Suchman L, Holt K. Análisis de narrativas del personal prestador de servicios anticonceptivos en México: entre la autonomía reproductiva y la coerción anticonceptiva. Cad Saude Publica [Internet]. 2025; 41(2):e00103324. DOI: 10.1590/0102-311XES103324

Downloads

Download data is not yet available.